Myriad Genetics, Inc.
$5.14
▲
3.49%
2026-04-21 08:19:00
www.myriad.com
NMS: MYGN
Explore Myriad Genetics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$484.84 M
Current Price
$5.14
52W High / Low
$8.59 / $3.76
Stock P/E
—
Book Value
$3.94
Dividend Yield
—
ROCE
-11.84%
ROE
-23.51%
Face Value
—
EPS
$-3.95
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,700
Beta
1.64
Debt / Equity
32.84
Current Ratio
2.67
Quick Ratio
2.26
Forward P/E
25.91
Price / Sales
0.73
Enterprise Value
$256.06 M
EV / EBITDA
-2.29
EV / Revenue
0.46
Rating
Hold
Target Price
$7.78
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | XWELL, Inc. | $1.2 | — | $9.7 M | — | -75.03% | -275.96% | $2.2 / $0.26 | $-1.1 |
| 2. | Mettler-Toledo International Inc. | $1,328.56 | 31.6 | $26.93 B | — | 44.48% | -1154.87% | $1,525.17 / $962.54 | $-1.16 |
| 3. | Veracyte, Inc. | $33.45 | 39.66 | $2.63 B | — | 5.82% | 5.34% | $50.71 / $22.61 | $16.5 |
| 4. | Medpace Holdings, Inc. | $513.23 | 33.75 | $14.67 B | — | 84.68% | 70.23% | $628.92 / $250.05 | $16.18 |
| 5. | Labcorp Holdings Inc. | $271.17 | 25.93 | $22.36 B | 1.07% | 9.74% | 10.51% | $293.72 / $209.38 | $104.86 |
| 6. | Twist Bioscience Corporation | $61.88 | — | $3.79 B | — | -24.75% | -16.79% | $62.09 / $23.3 | $7.44 |
| 7. | ICON Public Limited Company | $114.42 | 15.51 | $8.76 B | — | 8.66% | 6.27% | $211 / $66.57 | $122.25 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 209.8 M | 205.7 M | 213.1 M | 195.9 M | 210.6 M | — |
| Operating Profit | -3 M | -23.3 M | -12.5 M | -29 M | -17.3 M | — |
| Net Profit | -7.9 M | -27.4 M | -330.5 M | -0.1 M | -42.5 M | — |
| EPS in Rs | -0.08 | -0.29 | -3.53 | -0 | -0.45 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 824.5 M | 837.6 M | 753.2 M | 678.4 M |
| Operating Profit | -67.8 M | -88 M | -144.6 M | -123.7 M |
| Net Profit | -365.9 M | -127.3 M | -263.3 M | -112 M |
| EPS in Rs | -3.91 | -1.36 | -2.82 | -1.2 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 706.6 M | 1.03 B | 1.15 B | 1.2 B |
| Total Liabilities | 338.6 M | 326.5 M | 363.3 M | 312.9 M |
| Equity | 368 M | 701.1 M | 783.2 M | 885.8 M |
| Current Assets | 332.6 M | 298 M | 313.6 M | 274.6 M |
| Current Liabilities | 133.8 M | 164.1 M | 155.9 M | 137.2 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 1.8 M | -8.7 M | -110.9 M | -106.3 M |
| Investing CF | -27.4 M | -11.9 M | 31.9 M | -77.5 M |
| Financing CF | 64.2 M | -7.4 M | 152.9 M | -8 M |
| Free CF | -25.6 M | -38.4 M | -184.2 M | -151.6 M |
| Capex | -27.4 M | -29.7 M | -73.3 M | -45.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 11.21% | 11.03% | — | — |
| Earnings Growth % | 51.65% | -135.09% | — | — |
| Profit Margin % | -15.2% | -34.96% | -16.51% | — |
| Operating Margin % | -10.51% | -19.2% | -18.23% | — |
| Gross Margin % | 69.89% | 68.64% | 70.22% | — |
| EBITDA Margin % | -7.1% | -26.21% | -12.49% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.